Evaluating outcomes of a clinical pharmacist medication management program in a multidisciplinary practice for outpatient buprenorphine treatment of opioid use disorder

被引:8
|
作者
Mattle, Anna G. [1 ,2 ,3 ]
Aladeen, Traci [1 ,3 ]
Blondell, Richard D. [4 ]
Capote, Horacio [5 ]
Rainka, Michelle [1 ,3 ]
机构
[1] Univ Buffalo, Dept Pharm Practice, Buffalo, NY 14260 USA
[2] Univ Buffalo, Dept Pharmaceut Sci, Buffalo, NY 14260 USA
[3] Dent Neurol Inst, Div Neuropharmacol, Buffalo, NY 14226 USA
[4] Univ Buffalo, Dept Family Med, Buffalo, NY USA
[5] Dent Neurol Inst, Div Neuropsychiat, Buffalo, NY USA
关键词
addiction; buprenorphine; medications for opioid use disorder; medication-assisted treatment; multidisciplinary; opioids; opioid use disorder; outpatient; pharmacist; CARE;
D O I
10.1002/jac5.1405
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction Treatment with medications such as buprenorphine has been shown to improve outcomes of patients with opioid use disorder (OUD); however, there is still potential to optimize care. Clinical pharmacists may benefit OUD patient treatment by making individualized medication recommendations and enhancing care as part of a multidisciplinary team. This study evaluates a novel outpatient practice model that incorporates pharmacists to manage OUD patients. Methods A multi-center retrospective study compared outcomes of a multidisciplinary practice with clinical pharmacists to a physician-only practice. Primary outcomes were treatment retention and opioid relapse rate. Secondary outcomes included patient engagement with counseling, toxicology results, and buprenorphine nonadherence. Data were collected from 75 patient records from each practice for up to 1 year after starting treatment. In addition, a prospective, observational study was conducted to describe pharmacist interventions at the multidisciplinary practice. Twenty patients were followed for up to 1 year to characterize pharmacist recommendations and assess treatment retention and opioid relapse rates among other secondary measures. Results In the retrospective study, treatment retention did not differ between practices (P > .05) but multidisciplinary practice patients experienced fewer opioid relapse months (P < .05). Similar rates of engagement with counseling (P = 1) and follow-up visits with illicit substance use (P > .05) were observed. More buprenorphine nonadherence was identified at the physician practice (P < .01). In the prospective study, pharmacist recommendations included buprenorphine regimen changes and the addition of new medications for un/undertreated conditions. Pharmacists provided care coordination, medication counseling, non-pharmacologic recommendations, and counseling regarding future/alternative treatment options. Conclusion This study demonstrates the ability of a practice with clinical pharmacists to provide quality care to OUD patients in an outpatient setting. These results have implications for OUD treatment by expanding addiction services in this underserved patient population.
引用
收藏
页码:424 / 434
页数:11
相关论文
共 50 条
  • [41] Sorting through life: evaluating patient-important measures of success in a medication for opioid use disorder (MOUD) treatment program
    Megan K. Reed
    Kelsey R. Smith
    Francesca Ciocco
    Richard W. Hass
    Avery Lin Cox
    Erin L. Kelly
    Lara C. Weinstein
    [J]. Substance Abuse Treatment, Prevention, and Policy, 18
  • [42] Medication-Assisted Treatment for Opioid Use Disorder in a Rural Family Medicine Practice
    Deyo-Svendsen, Mark
    Cabrera Svendsen, Matthew
    Walker, James
    Hodges, Andrea
    Oldfather, Rachel
    Mansukhani, Meghna P.
    [J]. JOURNAL OF PRIMARY CARE AND COMMUNITY HEALTH, 2020, 11
  • [43] Creation of an algorithm for clinical decision support for treatment of opioid use disorder with buprenorphine in primary care
    Adriane M. dela Cruz
    Robrina Walker
    Ronny Pipes
    Sidarth Wakhlu
    Madhukar H. Trivedi
    [J]. Addiction Science & Clinical Practice, 16
  • [44] Creation of an algorithm for clinical decision support for treatment of opioid use disorder with buprenorphine in primary care
    dela Cruz, Adriane M.
    Walker, Robrina
    Pipes, Ronny
    Wakhlu, Sidarth
    Trivedi, Madhukar H.
    [J]. ADDICTION SCIENCE & CLINICAL PRACTICE, 2021, 16 (01)
  • [45] A Systematic Review and Meta-Analysis of Studies Evaluating the Effect of Medication Treatment for Opioid Use Disorder on Infectious Disease Outcomes
    McNamara, Katelyn F.
    Biondi, Breanne E.
    Hernandez-Ramirez, Raul U.
    Taweh, Noor
    Grimshaw, Alyssa A.
    Springer, Sandra A.
    [J]. OPEN FORUM INFECTIOUS DISEASES, 2021, 8 (08):
  • [46] Feasibility and outcomes from an integrated bridge treatment program for opioid use disorder
    Langabeer, James R.
    Champagne-Langabeer, Tiffany
    Yatsco, Andrea J.
    O'Neal, Meredith M.
    Cardenas-Turanzas, Marylou
    Prater, Samuel
    Luber, Samuel
    Stotts, Angela
    Fadial, Tom
    Khraish, Gina
    Wang, Henry
    Bobrow, Bentley J.
    Chambers, Kimberly A.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF EMERGENCY PHYSICIANS OPEN, 2021, 2 (02)
  • [47] Concomitant use of buprenorphine for medication-assisted treatment of opioid use disorder and benzodiazepines: Using the prescription behavior surveillance system
    Zhu, Yanmin
    Coyle, D. Tyler
    Mohamoud, Mohamed
    Zhou, Esther
    Eworuke, Efe
    Dormitzer, Catherine
    Staffa, Judy
    [J]. DRUG AND ALCOHOL DEPENDENCE, 2018, 187 : 221 - 226
  • [48] Concomitant Use of Buprenorphine for Medication-Assisted Treatment of Opioid Use Disorder and Benzodiazepines: Using the Prescription Behavior Surveillance System
    Zhu, Yanmin
    Coyle, D. Tyler
    Mohamoud, Mohamed
    Zhou, Esther
    Eworuke, Efe
    Dormitzer, Catherine
    Staffa, Judy
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 : 16 - 17
  • [49] Depression history as a predictor of outcomes during buprenorphine-naloxone treatment of prescription opioid use disorder
    Peckham, Andrew D.
    Griffin, Margaret L.
    McHugh, R. Kathryn
    Weiss, Roger D.
    [J]. DRUG AND ALCOHOL DEPENDENCE, 2020, 213
  • [50] Implementation and Clinical Outcomes of an Employer-Sponsored, Pharmacist-Provided Medication Therapy Management Program
    Theising, Katie M.
    Fritschle, Traci L.
    Scholfield, Angelina M.
    Hicks, Emily L.
    Schymik, Michelle L.
    [J]. PHARMACOTHERAPY, 2015, 35 (11): : E159 - E163